scholarly journals Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

2021 ◽  
Vol Volume 13 ◽  
pp. 7187-7201
Author(s):  
Cheng-Yu Chang ◽  
Chung-Yu Chen ◽  
Shih-Chieh Chang ◽  
Yi-Chun Lai ◽  
Yu-Feng Wei
Keyword(s):  
Kinase Inhibitor ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Mutated ◽  
Inhibitor Treatment

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

Lung Cancer ◽  
2009 ◽  
Vol 66 (1) ◽  
pp. 97-102 ◽  
Author(s):  
L. Johnetta Blakely ◽  
Lee Schwartzberg ◽  
Mark Keaton ◽  
Fred Schnell ◽  
David Henry ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase Ii Trial ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

2010 ◽  
Vol 5 (3) ◽  
pp. 361-368 ◽  
Author(s):  
Young Joo Lee ◽  
Heung Tae Kim ◽  
Ji-Youn Han ◽  
Tak Yun ◽  
Geon Kook Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
First Line ◽  
Gefitinib Treatment
Sign in / Sign up

Export Citation Format

Share Document